Sec Form 13D Filing - Canaan XI L.P. @ Day One Biopharmaceuticals Inc.

Sec Form 13D Filing - Canaan XI L.P. filing for Day One Biopharmaceuticals Inc. (DAWN) - 2022-09-22

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-101)

INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)

AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. 3)*

DAY ONE BIOPHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

23954D109

(CUSIP Number)

Canaan XI L.P.

c/o Canaan Partners

285 Riverside Avenue, Suite 250

Westport, Connecticut 06880

(203) 855-0400

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 21, 2022

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d 1(e), 240.13d 1(f) or 240.13d 1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 23954D109		SC 13D/A		Page 2 of 7


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Canaan XI L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands

* Calculated based upon 73,461,100 outstanding shares of Common Stock of the Issuer as of August 1, 2022, as reported by the Issuer in its Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on August 4, 2022.


CUSIP No. 23954D109		SC 13D/A		Page 3 of 7


1.		Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Canaan Partners XI LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware


CUSIP No. 23954D109		SC 13D/A		Page 4 of 7

EXPLANATION.

This Amendment No. 3 to Schedule 13D (“Amendment No. 3”) relates to Common Stock, par value $0.0001 per share (the “Common Stock”), of Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and is being filed on behalf of the Reporting Persons. This Amendment No. 3 amends and supplements Amendment No. 2 previously filed with the SEC (as defined below) on September 19, 2022 (“Amendment No. 2”), Amendment No. 1 previously filed with the SEC (as defined below) on December 22, 2021 (“Amendment No. 1”), and the initial Schedule 13D previously filed with the Securities and Exchange Commission (the “SEC”) by the Reporting Persons on June 10, 2021 (the “Initial Schedule 13D”, together with, Amendment No. 1, Amendment No. 2 and this Amendment No. 3, the “Schedule 13D”). Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. The Common Stock is held directly by Canaan XI L.P.

ITEM 5.

INTEREST IN SECURITIES OF THE ISSUER.

Paragraphs (a), (b) and (c) of this Item 5 are amended and restated as follows:

(a) and (b) As of the date of this Schedule 13D, Canaan XI directly beneficially owns 6,964,301 shares of Common Stock, representing approximately 9.5% of the total outstanding shares of Common Stock based upon 73,461,100 outstanding shares of Common Stock of the Issuer as of August 1, 2022, as reported by the Issuer in its Form 10-Q for the quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on August 4, 2022.

As of the date of this Schedule 13D, Canaan XI GP may be deemed to beneficially own the shares held directly by Canaan XI.

(c) Information with respect to transactions in the shares beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth on Annex I attached hereto and incorporated herein by reference. Additionally, on September 21, 2022, Canaan XI effected a pro rata distribution, for no consideration, of 1,500,000 shares to its partners.

ITEM 7.

MATERIAL TO BE FILED AS EXHIBITS.

Exhibit 99.1

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended


CUSIP No. 23954D109		SC 13D/A		Page 5 of 7

Annex I

Information with Respect to Transactions during the Past 60 Days


Date	Transaction	Shares	Price/Share ($)
09/19/2022	Sell	76,725	$20.57 (1)
09/20/2022	Sell	146,404	$19.50 (2)
09/20/2022	Sell	2,266	$20.10 (3)
09/21/2022	Sell	607,497	$18.54 (4)
09/21/2022	Sell	6,106	$19.29 (5)

(1)

The price reported in the Price/Share ($) column above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22—$21.07, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2)

The price reported in the Price/Share ($) column above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06—$19.85, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3)

The price reported in the Price/Share ($) column above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06—$20.15, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(4)

The price reported in the Price/Share ($) column above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27—$19.26, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(5)

The price reported in the Price/Share ($) column above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27—$19.35, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


CUSIP No. 23954D109		SC 13D/A		Page 6 of 7

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: September 22, 2022


CANAAN XI L.P.

By:		Canaan Partners XI LLC, its general partner

By:		/s/ Nancy Levenson
		Nancy Levenson Attorney-in-Fact


CANAAN PARTNERS XI LLC

By:		/s/ Nancy Levenson
		Nancy Levenson Attorney-in-Fact


CUSIP No. 23954D109		SC 13D/A		Page 7 of 7

EXHIBIT INDEX


Exhibit No.		Description

99.1		Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

6,964,301

Shared Voting Power

0

Sole Dispositive Power

6,964,301

Shared Dispositive Power

0